Get started
Author

Mark Sanders Womack

Observed names: M Womack, M. Womack, Mark S. Womack, Mark Womack
OpenAlex ID: A5084149387
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
2019 · Cathy Eng, Tae Won Kim, et al. · The Lancet Oncology · 571
Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
2022 · Margaret A. Tempero, Uwe Pelzer, et al. · Journal of Clinical Oncology · 146
PDF
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
2017 · Andrew H. Ko, Patrick B. Murphy, et al. · The Oncologist · 50
PDF
Results of a Randomized, Double-Blind, Placebo-Controlled, Phase 1b/2 Trial of Nabpaclitaxel + Gemcitabine ± Olaratumab in Treatment-Naïve Participants with Metastatic Pancreatic Cancer
2024 · Faithlore P. Gardner, Zev A. Wainberg, et al. · Cancers · 4
PDF
RAINIER: A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) combined with apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC).
2016 · Andrew H. Ko, Patrick B. Murphy, et al. · Journal of Clinical Oncology · 4
323P NALIRIFOX versus nab-paclitaxel and gemcitabine (Gem+NabP) in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Subgroup analysis of patients aged 65 years or older in NAPOLI 3
2024 · T. Macarulla Mercade, R.A. Pazo Cid, et al. · Annals of Oncology · 3
DKN-01 plus bevacizumab and chemotherapy as second-line (2L) investigational therapy in advanced microsatellite stable (MSS) colorectal adenocarcinoma (CRC): DeFianCe trial.
2024 · Meredith Pelster, John H Strickler, et al. · Journal of Clinical Oncology · 3
PDF
A phase II study of nab-paclitaxel plus ramucirumab for the second-line treatment of patients with metastatic gastroesophageal cancer.
2020 · Johanna C. Bendell, Ivor John Percent, et al. · Journal of Clinical Oncology · 3
A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
2019 · Uwe Pelzer, Johanna C. Bendell, et al. · Journal of Clinical Oncology · 3
A phase 1b (open-label)/phase 2 (randomized, double-blinded) study evaluating nab-paclitaxel and gemcitabine with or without olaratumab in first-line treatment of metastatic pancreatic cancer.
2018 · Johanna C. Bendell, Uwe Pelzer, et al. · Journal of Clinical Oncology · 2
A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC): The RAINIER trial.
2016 · Andrew H. Ko, Patrick Brian Murphy, et al. · Journal of Clinical Oncology · 2
Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VEGF pathways with casdozokitug (casdozo, SRF388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced, or metastatic hepatocellular carcinoma (uHCC).
2024 · Daneng Li, Kun-Ming Rau, et al. · Journal of Clinical Oncology · 1
1475P Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer
2021 · F. Gardner, Z. Wainberg, et al. · Annals of Oncology · 1
PDF
A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.
2014 · Johanna C. Bendell, James D. Peyton, et al. · Journal of Clinical Oncology · 1
Works count: 14
Citation count: 792
H-index: 4
I10-index: 3
Year
Topic
Type